Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

NCT07760155 is registered in ClinicalTrials.gov with Shanghai Escugen Biotechnology Co., Ltd as lead sponsor.

NCT NCT07760155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07760155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Lead sponsor
Shanghai Escugen Biotechnology Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 30, 2028
Enrollment
40 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)